CellEDIT - CRISPR-Edited C2C12 Cell Line
Let us support you with a custom, high-quality engineered C2C12 cell line.
We'll handle the CRISPR engineering of your C2C12 cells, so you focus on your research.
C2C12 is a mouse myoblast cell line which quickly differentiates to form contractile myotubes and produce characteristic muscle proteins.
C2C12 Cell Line Information
Organism
Mouse
Tissue Type
Muscle
Cell Type
Myoblast
C2C12 Cell Line Applications
Muscle Development and Differentiation: C2C12 cells are myoblast cells that can be readily differentiated into myotubes and are therefore extensively used to study the mechanisms of muscle development, differentiation, and regeneration.
Gene Expression Studies: Researchers utilize C2C12 cells to investigate the regulation of gene expression during muscle cell differentiation, providing insights into muscle-specific genes and transcriptional control mechanisms.
Drug Screening and Development: The cell line is employed in testing the effects of various compounds on muscle cells, aiding in the discovery and development of drugs for muscle-related diseases and conditions.
Muscle Disease Modeling: C2C12 cells are used to model muscle diseases, such as muscular dystrophy, enabling researchers to study disease pathology and potential therapeutic approaches.
Tissue Engineering and Regenerative Medicine: The cell line is used to develop and test scaffolds and other materials intended for muscle repair and regeneration in regenerative medicine applications.
Related Case Studies
Maximize your research potential with CellEDIT’s expertise. A custom CRISPR-edited C2C12 cell line is crucial for studying muscle development and differentiation, as it can differentiate into myoblast and myotubes. It provides valuable insights into gene expression regulation during muscle formation and is widely used in drug screening for muscle-related diseases. Additionally, C2C12 cells are essential for modeling muscle diseases and advancing tissue engineering and regenerative medicine research. With the CellEDIT workflow, we can provide you with custom and monoclonal knockout C2C12 cell lines suited for your project needs, with a 10-week delivery time.
Efficient on
Hard-to-transfect cells
Vector-free
direct intra-nuclear delivery
Minimized Off-Target
Immortalized Cells
Find out how
the CellEDIT workflow enabled the generation of 5 monoclonal HPRT knockout C2C12 cell lines through direct intra-nuclear injection of only 51 cells.
Hard-to-Transfect Cells
Discover how
the CellEDIT workflow facilitated the production of 3 monoclonal HPRT1 knockout SK-MES-1 cell lines, which are notoriously hard-to-transfect.
Available Edits using CellEDIT Engineered Cells
Knockout
Save time in the lab by empowering your research with CellEDIT. Confidently streamline your drug discovery workflow and investigate gene function with effective CRISPR knockouts.
Multiplex Editing
At CellEDIT, we provide you with multiplexed cell lines in 10 weeks. The efficiency and gentleness of our vector-free editing through intra-nuclear delivery, makes it an ideal system to perform multiplex gene editing in one go.
Related Resources
Educational
Technical
Introduction to CRISPR Knockout Gene Editing with CellEDIT
An Overview of CellEDIT' CRISPR Cell Line Development Services
CellEDIT' CRISPR Cell Line Development Workflow
CellEDIT's Engineered Cell Lines
CRISPR-Edited KPC Cell LineCRISPR-Engineered U2OS Cell Line
CRISPR-Engineered MDA MB 231 Cell Line
CRISPR-Engineered A549 Cell Line
CRISPR-Edited Hek293 Cell Line
Media & Downloads
On-Demand CellEDIT's CRISPR Cell Line Engineering Webinar
CellEDIT's Application Note n*1 - Introducing the CellEDIT Workflow
CellEDIT's Application Note n*2 - Overcoming the hard-to-transfect cell line hurdle
Open Access Publication featuring CellEDIT: Antony, Justin S., Anabel Migenda Herranz, Tahereh Mohammadian Gol, Susanne Mailand, Paul Monnier, Jennifer Rottenberger, Alicia Roig‐Merino et al. " Accelerated generation of gene-engineered monoclonal CHO cell lines using FluidFM nanoinjection and CRISPR/Cas9" Biotechnology Journal 19, no. 4 (2024): 2300505.